about
State of the science in cervical cancer: where we are today and where we need to goCD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.Microenvironment and pathogenesis of epithelial ovarian cancerEffects of the tumor microenvironment on the efficacy of tumor immunotherapy.Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunityRecent advances in strategies for immunotherapy of human papillomavirus-induced lesions.alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumorsModulating the tumor immune microenvironment as an ovarian cancer treatment strategy.Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunityIn situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Emerging drugs for ovarian cancer
P2860
Q27027042-97D25EDB-08C9-4643-A1DC-74E0AF3312B4Q34352531-7783DB84-A787-49B6-81EB-54A6D003FD41Q35244923-59AF7412-87ED-49E3-8E3E-50F7A08EED2FQ35419057-0105993C-73EC-4F1A-871B-30A4F37B23E8Q36569004-BD660E58-D520-4E42-B881-84B456874466Q36643661-1F6A34B0-AD1C-4B87-B9B0-EE836EE5ED89Q36693023-470E03DB-0AAA-4229-ABC6-2DFE23CF2BD9Q36987072-7F2AEA27-6747-4AB8-9EF4-C6879508CC37Q37002097-FB3629E4-0E87-465C-80E0-26C45CCD9CACQ37169908-C0FE08CA-2335-47F6-922E-018305A46459Q37286656-FD4A0D29-01F7-4B13-9827-9F7D4E630D10Q37369512-D2FF19FF-9962-4EF2-A52B-5270F646830BQ37369523-1EE74425-9FBF-45E1-A1CE-5AD9C8AB4A43Q37371532-FE81E049-827D-4968-9DA1-9E868E81EB13Q37836612-4D9C47C2-F776-4FF6-AB60-0E220B49C25FQ38217028-B12A99D9-AD35-40B9-A734-37CD3DE9FCBAQ57903790-FDCC29B8-CED9-4B3B-9D92-A85F2A88EF51
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunotherapy for gynaecological malignancies.
@ast
Immunotherapy for gynaecological malignancies.
@en
type
label
Immunotherapy for gynaecological malignancies.
@ast
Immunotherapy for gynaecological malignancies.
@en
prefLabel
Immunotherapy for gynaecological malignancies.
@ast
Immunotherapy for gynaecological malignancies.
@en
P2093
P2860
P1476
Immunotherapy for gynaecological malignancies
@en
P2093
Jose R Conejo-Garcia
Richard B S Roden
P2860
P304
P356
10.1517/14712598.5.9.1193
P407
P577
2005-09-01T00:00:00Z